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Vaginal infections are common in women of all ages and proper treatment is essential. The 
vaginal route of administration can be considered as favourable for the local therapy of vaginal 
infections. There are several vaginal dosage forms currently available; however, all suffer from 
limitations such as leakage and limited residence time at the site of action resulting in reduced 
therapeutic effect. Epicatechin (EC) is thought to be a potential substance in the both prevention 
and treatment of vaginal infections due to its antioxidative and anti-inflammatory effects, 
potentially also antimicrobial. However, the physiochemical properties of EC limit its use, and 
EC is a good candidate to exploit the beneficial effects of delivery system on improved 
therapeutic action. A delivery system with suitable viscosity and good mucoadhesive properties 
was the focus of this project; liposomal hydrogel comprising liposomes containing EC and 
chitosan hydrogel as a vehicle was developed.  
Phosphatidylcholine liposomes containing EC were made by the thin film method followed by 
extrusion to desired size of 200 nm. Liposomal EC were characterized for vesicle size, 
polydispersity and EC entrapment efficiency. We prepared liposomes of desired vesicle size 
(around 200 nm) with rather high EC load (over 80 % entrapment efficacy). Liposomal EC 
suspensions were further incorporated in a chitosan hydrogel vehicle, and the texture properties 
of the hydrogel investigated to optimize the formulation. The hydrogels were found to have 
satisfactory cohesiveness, adhesiveness and hardness as well as satisfactory mucoadhesive 
properties, however, further investigation and optimization of the method is needed. Liposomal 
EC and liposomal EC hydrogel were found to provide prolonged EC release. High 
accumulation of EC at the ex vivo vaginal tissue confirmed that liposomal EC hydrogels could 
assure localized vaginal delivery.  
 






Abstract (Norwegian)  
Vaginale infeksjoner er vanlig hos kvinner i alle aldre, og riktig behandling er viktig. Den 
vaginale administrasjonsveien kan anses som gunstig for lokal behandling av vaginale 
infeksjoner. Det finnes per dags dato mange vaginale doseringsformer, men begrensninger som 
lekkasje og redusert retensjonstid på administrasjonsstedet kan resultere i redusert terapeutisk 
effekt. Epicatechin (EC) er antatt å være en substans som potensielt kan brukes i forebygging 
og behandling av vaginale infeksjoner på grunn av dets anti-inflammatoriske, antioksiderende 
og potensielt antimikrobielle effekt. De fysikalske og kjemiske egenskapene til EC gjør det 
vanskelig å utnytte disse effektene, og et egnet leveringssystem er nødvendig for å bedre den 
terapeutiske virkningen. For å utvikle et leveringssystem for EC med passende viskositet og 
gode slimhinneklebende egenskaper for vaginal applikasjon, var fokuset i dette prosjektet å 
utvikle en liposomal hydrogel som inneholder liposomer med EC.  
Liposomer laget av fosfatidylkolin med EC inkorporert ble fremstilt ved hjelp av tynnfilm 
metoden etterfulgt av ekstrudering til ønsket vesikkel størrelse på 200 nm. Liposomene ble 
karakterisert for deres størrelse, størrelsesfordeling og mengde EC inkorporert. Vi fremstilte 
liposomer med ønsket vesikkelstørrelse (rundt 200 nm) med ganske høyt innhold av inkorporert 
EC (80 %). Videre ble liposomene inkorporert i en kitosan hydrogel, der hydrogelens 
teksturegenskaper ble undersøkt for å optimalisere formuleringen. Hydrogelen hadde god 
kohesivitet, adhesivitet og hardhet. I tillegg hadde hydrogelene gode slimhinneklebende 
egenskaper, men ytterligere undersøkelser og optimalisering av metoden er nødvendig. 
Liposomal EC og liposomal EC hydrogel ble funnet å gi en forlenget frisetting av substansen. 
Høy akkumulering av EC på ex vivo vaginalt vev bekreftet at liposomal EC hydrogel kunne 
sikre en lokalisert vaginal levering. 
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1 General introduction  
According to the World Health Organization (WHO) and other research centres such as the U.S 
Centre for Disease Control and Prevention, the incidence of sexually transmitted infections 
(STIs) has increased and represents a major health problem affecting both female and male 
population (Blakney et al., 2017; Satterwhite et al., 2013). Further, the most common viral 
infections are caused by human papilloma virus (HPV) and Herpes simplex virus (HSV) which 
have specific therapeutic challenges (Viera et al., 2010). Today’s treatment of HSV and HPV 
is limited due to challenges in the complete elimination of viruses. The therapy should therefore 
aim to treat symptoms and prevent recurrence. There is an urgent need for improved treatment 
options.  
Vaginal infections are common in women of all ages and proper treatment is essential in order 
to avoid serious consequences of failed therapy such as infertility, preterm delivery and 
induction of malignancy (Fenton and Lowndes, 2004). Vaginitis is an inflammation in the 
vagina often caused by vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis (Quan, 
2010). Topical or oral treatment of those infections are found to be equally efficient, however, 
local treatment is preferred due to minimal side effects. To obtain an efficient local treatment, 
the design of effective topical formulation should consider the characteristics of infected 
vaginal site (Palmeira-de-Oliveira et al., 2015). The vaginal self-cleansing mechanism 
contributes to reduced therapeutic effect of currently available drug dosage forms (Baloglu et 
al., 2009). Thus, the development of an effective drug delivery system that can prolong the 
residence time and enable sustained release of incorporated drug for improved drug therapy is 
needed.  
Natural polyphenols are considered one of the most promising nutraceuticals in health care and 
have been recently investigated for the prevention and treatment of STIs (Date and Destache, 
2016). Catechins are natural polyphenols found in green tea, of which epicatechin (EC) is one 
of the primary catechin components. They are known to have strong antioxidant, antibacterial 
and antiviral activity, and are associated with many health benefits (Cabrera et al., 2006). 
However, EC suffers from poor solubility and low bioavailability, thus making the 
pharmacological properties hard to be fully utilized. Nanomedicine can improve the therapy 
outcome due to the potential to address some of the challenges that cause limited therapy (Vanić 
and Škalko-Basnet, 2013). By incorporating EC in suitable delivery systems, such as liposomes, 
these challenges can be overcome (des Rieux et al., 2006; Hu et al., 2017). Liposomes have 
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been widely used as drug carriers in different applications and are able to incorporate both 
lipophilic and hydrophilic compounds (Akbarzadeh et al., 2013). Liposomes have the ability to 
perform sustained and controlled release of entrapped compounds and are therefore considered 
suitable for vaginal applications. However, a major limitation of liposomes for topical 
application is their low viscosity resulting in reduced retention time at vaginal site. To overcome 
this challenge, liposomes can be incorporated in well suited vehicles, such as hydrogels, that 
will prolong the residence time at the vaginal site (Pavelić et al., 2001).  
Hydrogels are water-swollen polymeric gels made of natural or synthetic materials. Due to their 
soft and rubbery consistency they are similar to living tissue, making the hydrogels ideal for 
variety of applications, including those for vaginal administration (Ullah et al., 2015). 
Prolonged residence time at the vaginal site improves the therapy by increasing the contact time 
between the drug and the vaginal mucosa (Pavelić et al., 2001). Some hydrogels contain 
polymers with good mucoadhesive properties to prolong the residence time, such as chitosan. 
Chitosan is a natural polysaccharide compound exhibiting good mucoadhesive properties. The 
increased interest for medical and pharmaceutical applications of this polymer is due to its good 
biocompatibility, non-toxicity and antibacterial properties (Kast et al., 2002). Based on 
chitosan´s positively charged amino groups and the anionic substructures of the mucus, 
mucoadhesion can occur enabling an increased retention time at the site of application 
(Bernkop-Schnürch and Dünnhaupt, 2012). In addition, several factors will influence the 
mucoadhesion at the vaginal site. The challenging factors affecting the efficacy of this route of 
the administration are the variation in the amount of mucus, vaginal fluid, pH and the thickness 
of the epithelium (das Neves et al., 2010).  
Incorporating liposomes into a hydrogel can assure a high concentration of drug in surrounding 
tissue over an extended period of time (Hoare and Kohane, 2008). The focus of this project was 
to develop a delivery system with suitable viscosity and good mucoadhesive properties for 
vaginal application of EC. This was achieved by incorporating liposomes containing EC into a 
chitosan-based hydrogel.  
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2 Introduction 
2.1 Common vaginal infections 
Genital infections represent a major public health problem in the world, with an increasing 
incidence due to the lack of effective prevention and treatment strategies (Fenton and Lowndes, 
2004). According to World Health Organization (WHO) more than one million sexually 
transmitted infections (STIs) are acquired everyday worldwide (WHO, 2016). Vaginal 
infections can be caused by bacteria or viruses and changes in the vaginal microflora can 
increase the risk for infection (Nardis et al., 2013; Noyes et al., 2018). However, preventative 
and therapeutic methods are under investigation, mainly for STIs such as HSV, HPV and some 
vaginal bacterial infections (Blakney et al., 2017). 
 
2.1.1 Vulvovaginal candidiasis  
Vulvovaginal candidiasis is a common infection of the female genital tract, however, it is not 
considered a STI as candida is considered a part of the vaginal flora in reproductive age (Sobel, 
1997). Candida albicans can be referred to as an opportunistic pathogenic fungus that causes 
mucosal infections. It is considered that more than 85 % of vulvovaginal candidiasis is caused 
by Candida, and at least 75 % of all women will suffer from a candida infection at least once 
in their lifetime (De Bernardis et al., 2018). The vaginal microflora can be disturbed by different 
factors such as pregnancy, antibiotics and oral contraceptives, and disturbance of the normal 
vaginal microflora can result in infection caused by Candida (Sobel, 1988). The infection can 
take place by the adhesion of Candida to epithelial cells (De Bernardis et al., 2018). Candida 
infections can be treated both local and orally, and the efficacy is considered equal (Sobel, 
2014). Azole products as antifungal agents are widely used in the treatment of Candida 
infections. There are several advantages in local drug therapy such as reduced systemic drug 
exposure and reduced incidence of adverse effects (das Neves et al., 2015).  
 
2.1.2 Human papilloma virus 
Human papilloma virus (HPV) is a non-enveloped virus in the Papillomaviridae family (zur 
Hausen, 2002). HPV is an infectious organism and one of the most common STIs which gets 
transmitted through mucosal surfaces (Bansal et al., 2016; Forcier and Musacchio, 2010). 
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Several HPV subtypes have been identified and are categorized as high- and low risk HPV 
infections (zur Hausen, 2002). High risk mucosal HPV types 16 and 18 are associated with 
cervical and vaginal cancers (Boda et al., 2018). HPV is also responsible for genital warts, 
where low-risk HPV type 6 and 11 are responsible for 85 % of the cases (Joura and Pils, 2016). 
Even if HPV is known to be responsible of cervical and vaginal cancer, the infections are often 
underestimated, asymptomatic and unrecognized (Boda et al., 2018). Currently there are no 
antiviral therapy for HPV infections, and for genital warts the treatment is often a combination 
of removal of the warts combined with local treatment. Polyphenon E (sinecatechins 15 % 
ointment) is a local treatment approved by the Food and Drug Administration (FDA) for 
external genital warts where the active ingredients are green tea catechins which is thought to 
have antioxidant, antiviral and antitumor activities (Fathi and Tsoukas, 2014). There are 
developed vaccines for prevention of HPV infections composed of virus-like particles (Dillner 
et al., 2007). Another great potential in the treatment of HPV infections is the use of interferon 
alpha (IFN-a) (Kollipara et al., 2015).  
 
2.1.3 Herpes simplex virus 
HSV is one of the most common STIs that is transmitted by direct contact with infected 
individuals. There are two main types of HSV, where HSV-1 infections affect the face and 
HSV-2 is predominantly transmitted by sexual contact and is the major cause of genital herpes 
(Sauerbrei, 2016). Most genital HSV-2 infections are undiagnosed and unrecognized which 
contributes to the spreading of the virus (Gupta et al., 2007). HSV enters the body through 
mucus membranes and skin and then replicates within the epithelial cells. When infected, 
recurrent infections will occur, and studies show that HSV-2 infection presents an increased 
risk for obtaining HIV infections, which makes HSV a significant health concern (Gupta et al., 
2007). Another serious complication of genital herpes is neonatal transmission. Treatment of 
genital herpes with antiviral drugs aims to faster symptom resolution, healing and prevention 
of new lesions. The treatment does not eradicate infection or prevent new eruption (Gupta et 
al., 2007). Strategies to prevent HSV transmission and development of new antiviral products 
are under development, and many natural products from plants, such as EC, are under 
investigation (Docherty et al., 2005).  
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2.2 Vaginal anatomy and physiology  
The human vagina is the female genital, where the main functions are sexual intercourse and 
menstruation discharge. The vagina is an S-shaped tubular fibromuscular organ with a length 
around 6-9 cm that extends from the cervix of the uterus to the vaginal vestibule (das Neves 
and Bahia, 2006). The vaginal wall consists of four noticeable layers (Figure 1); stratified 
squamous epithelium, lamina propria, muscular layer and tunica adventicia (Wong et al., 2014).  
 
Figure 1: Schematic drawing of the vaginal mucosa. 1: capillary vessels; 2: artery; 3: vein (das 
Neves and Bahia, 2006). Copyright © with permission from RightsLink ® 
 
Stratified squamous epithelium is highly folded or “rougae” that increases the surface area and 
makes it suitable for drug absorption. The epithelial mucosa is covering the vaginal wall with 
a thickness of 200-300 µm (Wong et al., 2014). The thickness of the vaginal epithelium is age-
dependent and the epithelium changes through the menstrual cycle because of the variations in 
hormone levels (Poonia et al., 2006). The amount of estrogen decreases with increasing age, 
which leads to lower the thickness, discomfort and dryness.  
The vagina is referred to as a mucosal tissue although it does not have any secretory glands, 
however, a certain amount of fluid is secreted mainly by cervical cells (Vanić and Škalko-
Basnet, 2013). Studies are claiming that the daily vaginal fluid production is around 6 g 
(Palmeira-de-Oliveira et al., 2015). Vaginal fluid is a mixture composed of enzymes, proteins, 
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electrolytes, carbohydrates, amino acids and cervical mucus covering the vaginal wall (Wong 
et al., 2014). The vaginal mucus forms a viscoelastic barrier that protects the tissue from 
infections. The mucus layer consists of 95 % water, 1-2 % mucin glycoprotein fibers, and lower 
amounts of lactic acid, salts, proteins and enzymes. Mucin fibers are large molecules with size 
ranging from 0.5 to 40 million Daltons (Wong et al., 2014). The vaginal mucus has a rapid 
clearance that removes unwanted pathogens and particles before they reach the vaginal tissue. 
Changes in the vaginal fluid or mucus viscosity by environmental changes can reduce the 
protecting mucus barrier and increase the risk of infections (Palmeira-de-Oliveira et al., 2015). 
The mucus viscosity also varies depending on the menstrual cycle. When estrogen levels are 
high, the mucus consistency is thinner and more easily penetrable, and a decreasing estrogen 
levels increases the mucus viscosity (Caramella et al., 2015).  
pH in healthy premenopausal women varies between 4.5-5.5 (das Neves and Bahia, 2006). The 
acidic environment of the vagina is mainly caused by the lactobacilli that is a part of the natural 
microflora in the vagina. Lactobacilli converts glycogen into lactic acid that gives arise to the 
low pH (Boris and Barbés, 2000). Presence of menstrual blood, semen (pH 7.0 - 8.0) or disease 
can temporarily change the pH level (Vanić and Škalko-Basnet, 2017). The pH level may also 
be disturbed by sanitary products, soap and tampons. Maintenance of a normal vaginal pH is 
important for the prevention of microbial growth, that can cause vaginal infections (Fashemi et 
al., 2013). Additionally, the application of vaginal dosage forms could disturb the vaginal flora.  
 
2.2.1 Vaginal drug delivery 
The vagina has been used as a route for drug administration for several decades (Hussain and 
Ahsan, 2005). It is an acceptable site for local and systemic drug delivery with many advantages 
due to the large surface area, avoidance of first pass metabolism, good blood supply and drug 
penetration. The self-cleansing mechanism of the vagina is both an advantage and disadvantage 
because it offers the possibility of self-removal of the drug delivery system that is favorable, 
however the reduced retention time is a disadvantage. The vagina is less sensitive compared to 
ocular and buccal administrations and allows the presence of drug formulation for a longer 
period without irritating the administration site (das Neves et al., 2010). The vagina as a site of 
action also presents some limitation where the main is the gender specificity. Other 
disadvantages such as cultural issues about genital manipulation, insertion of objects in the 
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vagina, variability in drug absorption, personal hygiene, menopause and pregnancy can limit 
the vagina as a route for drug administration (das Neves et al., 2010).  
There are several vaginal dosage forms that are available at the market, such as vaginal rings, 
tablets, powders, capsules, suppositories, gels and creams. The most traditionally used vaginal 
products is for the locally active drugs such as antimicrobial, antiviral and contraceptives. The 
limitations with those dosage forms is that they suffer from leakage and limited residence time 
at the site of action because of the vaginal self-cleansing mechanism which may result in 
reduced effect (Baloglu et al., 2009). 
In the development of new vaginal formulations, vaginal physiology must be studied. The 
formulation must be suitable for this route of administration and to achieve a successful delivery 
system it has to overcome several factors. Some physical changing factors that may disturb the 
efficacy of this route of administration is by the presence of mucus and variation in the vaginal 
fluid, pH and thickness of the epithelium (das Neves et al., 2010). The physiochemical 
properties of the drug such as ionization, molecular weight and lipophilicity will affect the 
absorption through the vaginal epithelium. Another important factor to evaluate is, if it is for 
local or systemic treatment. For local therapy it is undesirable for the drug to be absorbed, 
especially for pregnant woman (Srikrishna and Cardozo, 2013).  
To obtain an optimal local therapeutic effect all the mentioned challenges should be overcome. 
It is also important that the delivery system is easy to use, non-toxic, non-irritating and painless 
to the patient. The drug concentration over a period of time at the administration site is 
important for a successful therapy (Srikrishna and Cardozo, 2013).This can be achieved by 
delivery systems with mucoadhesive properties.  
 
2.3 Mucoadhesion  
In pharmaceutical science, mucoadhesion is defined as when an adhesive material attaches to 
mucus or mucus membrane for an extended period of time by interfacial forces (das Neves et 
al., 2011a). Mucoadhesion can occur in two steps, the contact stage and consolidation stage 
(Figure 2). The contact stage is when the dosage forms intimate contact with the mucus 
membrane, and the consolidation stage is when various physiochemical interactions occurs 
between the dosage form and the mucus leading to a prolonged adhesion (Smart, 2005; das 
Neves et al., 2011a).  
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Figure 2: The two steps of mucoadhesion. 
 
The event of mucoadhesion is still not fully understood, and there are six general theories of 
adhesion. The first theory is the electronic theory that describes the adhesion as electron transfer 
between the mucoadhesive system and the mucus, forming an electrical double layer at the 
interface. The second theory is the wetting theory that is applied for liquid systems and 
describes the ability of a mucoadhesive liquid to spread onto a mucosal surface. The liquid may 
act as an adhesive depending on the contact angel of the mucoadhesive liquid and the mucosal 
surface. The third theory is the adsorption theory that describes the adhesion to the mucosa 
because of hydrogen bonds (van der Waals forces). The fourth theory is the diffusion theory 
which describes the interpenetration of polymeric chain to decent depth and a semipermanent 
adhesive bond occurs. The fifth theory is the mechanical theory which speculate that the 
irregularities on a rough surface makes the adhesive liquid to interlock together. The last theory 
is the fracture theory that define the force needed for the detachment of two involved surfaces. 
However, the mucoadhesion process is apparently achieved through a combination of several 
mentioned theories (Smart, 2005; Boddupalli et al., 2010; Vanić and Škalko-Basnet, 2014).  
The phenomena of mucoadhesion have been used to develop several dosage forms for oral, 
nasal, ocular and vaginal delivery. Mucoadhesive vaginal application enables reduced 
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administration frequency because of the prolonged residence time, better bioavailability and 
controlled delivery. For vaginal application the mucoadhesion may be affected by the vaginal 
environment and by the mucoadhesive properties of the polymer (Vanić and Škalko-Basnet, 
2014). 
 
2.3.1 Mucoadhesive polymers 
Mucoadhesive polymers can be divided into synthetic or natural polymers. Natural polymers 
such as alginates, chitosan, pectin, gelatine and synthetic polymers such as polyethylene glycol 
(PEG), carbomers and cellulose derivatives have been widely studied in application for vaginal 
drug administration (Roy et al., 2009). They can also be classified according to their chemical 
structure or their mechanism of binding (covalent, non-covalent). The surface charge of the 
polymers will also affect the adhesion mechanism (Hombach and Bernkop-Schnurch, 2010).  
Polymers diffuse into the mucosal layer and adhere to it by intermolecular complexes. The 
higher molecular mass of the polymer chains the greater mucoadhesion. The crosslinking 
reactions and the hydration of the polymer network effect the flexibility of the polymer chains 
and the mucoadhesion. Polymers can be manipulated and changed to increase their flexibility 
and mucoadhesive properties (Roy et al., 2009; Hombach and Bernkop-Schnurch, 2010). The 
existence of functional groups such as hydroxyl, amines and carboxyls on the polymers shows 
good capacity to stick to mucosal membranes and form adhesive bonds. An example of a 
polymer with functional groups is chitosan (Smart, 2005).  
 
2.3.2 Chitosan 
Chitosan exists in nature as chitin, which is a natural polysaccharide compound. It is the most 
abundant polysaccharide after cellulose (Hajji et al., 2014). The main sources are two marine 
shellfish; shrimp and crabs (Rinaudo, 2006). Chemical deacetylation of chithin is performed to 
produce the most common derivative, Chitosan. Chitosan is formed by connecting N-acetyl-2-
amino-2deoxy-D-glucoses through b-(1®4) glycoside bonds (Figure 3) (Hajji et al., 2014). 
Parameters that influence the characteristics of chitosan are molecular weight and its degree of 
deacetylation. These parameters can be modified during the chitosan preparation (Berger et al., 
2004a).  
 
Page 10 of 63 
 
Figure 3: Chemical structure of chitin and chitosan (Zuber et al., 2013). 
 
Chitosan has gained increased interest as medical and pharmaceutical applications due to its 
biocompatibility, non-toxicity, antimicrobial and mucoadhesive properties. Chitosan has been 
used as a controlled release delivery system for incorporated drugs in different formulations 
such as tablets, capsules and gels (Kast et al., 2002). Based on its positively charged amino 
groups and the anionic substructures of the mucus, mucoadhesion can occur and an increased 
retention time at the site of application (Bernkop-Schnürch and Dünnhaupt, 2012). This 
polymer is hydrophilic in nature and the ability of degradation by human enzymes makes the 
polymer biodegradable. Another advantage with chitosan is its antibacterial properties which 
is a benefit when treating vaginal infections (Ahmadi et al., 2015). To achieve a prolonged 
residence time in the vagina, chitosan can be used as a vehicle for the delivery system or as a 
surface modifying agent (das Neves and Bahia, 2006).  
 
2.4 Hydrogels 
Hydrogels are water swollen polymeric gels that are made of natural or synthetic materials, 
which possess a distinct three-dimensional structure. Because of their soft and rubbery 
consistency, they are similar to living tissue, making the hydrogels ideal for a variety of 
applications (Ullah et al., 2015). Hydrogels have several characteristics which make them 
excellent for drug delivery systems. The water content in hydrogels are high and they are 
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considered highly biocompatible, non-toxic and some are biodegradable (Bhattarai et al., 
2010). Some hydrogels contain polymers with good mucoadhesive and bioadhesive properties. 
Hydrogels with good mucoadhesive properties can enhance the residence time and are suitable 
for vaginal application (Bhattarai et al., 2010; Huang et al., 2000).  
Berger et al. classified hydrogels depending on the nature of their network, namely as entangled 
networks, covalently crosslinked networks and networks formed by secondary interactions 
(Berger et al., 2004a). They can also be classified based on the gelling material, if it is from 
natural or synthetic source, their degradability and physical structure. Radical polymerization 
is usually used for the preparation of polymers, then converted into hydrogels by crosslinking 
of the polymeric chains in moderately concentrated aqueous solutions (Parhi, 2017). The 
swelling part of hydrogels is a complex process with several steps. The first step is based on 
hydration of the hydrophilic groups of the hydrogel matrix, also known as primary bond water. 
The second step is interaction between water and hydrophobic groups and appears in the form 
of secondary bond water. Both the primary and secondary bound water forms the total bound 
water in the hydrogel. The third step is driven by osmotic force, and additional water is absorbed 
and fills the spaces between the chains and the centre of the larger pores (Ullah et al., 2015). 
Due to the crosslinked structure of hydrogels they do not disintegrate during swelling (Kopecek, 
2009).  
Chemical crosslinked hydrogels are a preparation method to produce permanent hydrogel 
networks by the presence of a chemical crosslinking agent. Crosslinking can be made by 
different methods such as crosslinking by radical polymerization, crosslinking by ionic 
interactions, crosslinking by crystallization and by chemical reaction of complementary groups 
(Ullah et al., 2015).  
Physically crosslinked gels have been extensively investigated over the past years as the use of 
crosslinking agents have been avoided (Ullah et al., 2015). Many crosslinking agents are toxic 
compounds which have to be removed from the hydrogel before used in 
biomedical/pharmaceutical applications. Physically crosslinked hydrogels are reversible bonds 
and generally biodegradable (Ullah et al., 2015). Under appropriate conditions physically 
crosslinked polymers are made spontaneously. Chitosan hydrogels are made by physical 
crosslinking, and the simplest way to prepare a chitosan hydrogel is by solubilisation of chitosan 
in an acidic aqueous medium. The main interaction between the networks are covalent bonds, 
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but other interactions such as hydrogen bridges and hydrophobic interactions may also occur 
(Berger et al., 2004b). 
 
2.4.1 Drug release from hydrogels 
Hydrogels have a highly porous structure which allows a large amount of substances to be 
incorporated (Jagur-Grodzinski, 2010). The benefits of local treatment with hydrogels is that 
they can maintain a high concentration of drug in the surrounding tissue over an extended period 
of time (Hoare and Kohane, 2008). Several factors influence the drug release from hydrogels 
and the release is based on the rate-limiting step for controlled release and categorized as: 
diffusion-controlled, swelling-controlled or chemically-controlled. The most applicable 
mechanism of drug release is the diffusion-controlled, where the release through the hydrogel 
mesh is the primary mechanism of release and is dependent of the mesh size within the gel 
matrix. If the diffusion is faster than the expansion of the hydrogel, then the swelling is 
considered to control the release. Chemically controlled release depends on the chemical 
reaction within the gel matrix (Bhattarai et al., 2010). The drug release can also be triggered by 
stimuli such as pH triggered release, enzymatic responsive release and electrical triggered 
release (Bhattarai et al., 2010). However, hydrogels are well suited vehicles for several 
substances and liposomes.  
 
2.5 Liposomes 
During the past years, nanotechnology-based delivery systems for medical purposes have 
gained an increased attention. Liposomes are attractive and physiological acceptable drug 
delivery nanosystems. They are widely used in advanced topical delivery of drugs by mucosal 
routes of administration (Vanić and Škalko-Basnet, 2014). Liposomes are spherical vesicles 
consisting of one or more phospholipid bilayers (also known as lamellae) surrounding aqueous 
units where the polar head groups are oriented in the interior and exterior aqueous phase 
(Figure 4). The liposomes are characterized by their particle size, numbers of lamellae, surface 
charge and inner/outer aqueous phase (Akbarzadeh et al., 2013).  
The motive to use liposomes as drug delivery systems was based on the possibility of fusion 
through the cell membrane, hence the preparation of liposomes had to be from lipids that was 
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present in the cell membrane. The biological membranes are composed of many different lipids 
such as glycerolipid, sphingolipids and sterols (Akbarzadeh et al., 2013). Liposomes can be 
prepared by different phospholipids, which will influence the properties of the liposomes, such 
as the rigidity or fluidity. Adding cholesterol to the liposomal membrane can increase the 
rigidity of the bilayer membrane and slow the disintegration of the liposomes (Choe et al., 1995; 
Arora et al., 2000).  
 
Figure 4: A unilamellar liposome with lipophilic drug incorporated in the phospholipid bilayer 
(Holsæter, 2004).  
 
One of the most commonly used phospholipids in liposomes is phosphatidylcholine (PC), also 
known as lecithin. PC and other lipids are amphipathic molecules with a hydrophobic and a 
hydrophilic component. The polar head group in PC is made of quaternary ammonium moiety 
choline that is linked to a phosphate group and then to a glycerol backbone by phosphoric ester. 
The PC tail is made of a fatty acid chain (Brandl, 2001). Phospholipids can be derived from 
both natural and synthetic sources. The main source is from vegetable oils and animals (i.e. 
soybean, corn, cotton seed, egg yolk and bovine brain) (Li et al., 2015).  
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Figure 5: Chemical structure of phosphatidylcholine and schematic illustration of 
phospholipid.  
 
Liposomes have many advantages as drug carriers for different substances, due to their 
biodegradability, biocompatibility and low toxicity. Liposomes have the ability to entrap both 
hydrophilic and lipophilic compounds, ensure controlled release and site-specific delivery of 
entrapped compounds, which makes them promising as pharmaceutical carriers (Akbarzadeh 
et al., 2013; Vanić and Škalko-Basnet, 2014). Various applications for liposomes are 
investigated and several formulations are on the market (Fan and Zhang, 2013). 
 
2.5.1 Preparation of liposomes  
Liposomes can be prepared by several methods with each process influencing liposome 
properties including size, lamellarity and entrapment efficiency (EE). The methods can be 
categorized into conventional or novel (Pattni et al., 2015).  
The first described method for liposome preparation was the Bangham method, also known as 
thin lipid film hydration (Bangham et al., 1967). The method is based on creating a thin film of 
lipids in a round bottom flask by evaporating the organic solvent. The lipid film was then re-
hydrated and hand shaken, causing the lipids to form liposomes spontaneously (Figure 6). With 
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the lipid film hydration method, size reduction of the liposomes may be needed. Size reduction 
can be generated by sonication or by multiple extrusions through a polycarbonate membrane 
(Pattni et al., 2015). The size of the liposomes depends on the number of extrusion cycles and 
the size of the polycarbonate pores in the extrusion membrane (Hope et al., 1985).  
 
Figure 6: Preparation of liposomes by film hydration method. 
 
The conventional methods have limitations such as low aqueous core entrapment and low EE 
for hydrophilic substances. This technique is for small-scale preparations and not convenient 
for industrial scale because of disadvantages such as board distribution, inconstant 
encapsulation and the difficulty with sterilization (Pattni et al., 2015). For industrial purpose, 
novel methods for preparation was developed. 
 
2.5.2 Classification of liposomes 
Liposomes are classified by their size and their lamellarity. The desirable size of liposomes in 
drug delivery applications are between 50 – 200 nm (Patil and Jadhav, 2014). The size of the 
liposomes can affect the circulation half-life of liposomes. Furthermore, liposomes can have 
one or many bilayer membranes (Akbarzadeh et al., 2013). Multilamellar vesicles (MLV) are 
liposomes with many membrane layers with a large diameter in size. They are usually over 100 
nm in size. Large unilamellar vesicles (LUV) are liposomes with a single layer membrane with 
a diameter between 100-1000 nm. Small unilamellar vesicles (SUV) are also liposomes with a 
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single layer membrane, but smaller in size with a diameter between 10-100 nm. Giant 
unilamellar vesicles (GUV) are single layer membrane liposomes with sizes up to 1 µm. 
Multivesicular liposomes are many small vesicles inside a bigger vesicle (Figure 7) (Samad et 
al., 2007; van Swaay and deMello, 2013). 
 
 
Figure 7: Liposomes classified by size and bilayers. SUV= small unilamellar vesicle, LUV= 
large unilamellar vesicle, GUV= Giant unilamellar vesicle, multilamellar and multivascular 
(van Swaay and deMello, 2013). Copyright © with permission from RightsLink ® 
 
Liposomes can also be classified by their lipid composition, which may affect the surface 
charge of the liposomes. The surface charge of liposomes can be negative, positive or neutral. 
Another type of liposomes are immunoliposomes. Those are modified liposomes with 
antibodies on the surface and are designed especially for targeted delivery (Eloy et al., 2017). 
Another class is long circulating liposomes, known as PEGylated liposomes (Samad et al., 
2007).  
Liposomes as drug carrier systems offers a sustained release of substances administrated 
topically, however the liquid nature of liposomes makes it difficult to achieve a prolonged 
retention at the administration site. Incorporating liposomes in hydrogels can reduce the 
frequency of administration and better the treatment of vaginal infections (Hurler et al., 2012a). 
Liposomes are acceptable carriers for different substances that are poorly soluble and undergoes 
enzymatic degradation such as EC, which is a substance found in green tea. Incorporating EC 
into liposomes can protect it from degradation and enhance the stability of the substance (Date 
and Destache, 2016).  
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2.6 Green tea catechins  
Green tea (Cammelia sinensis) is one of the most popular beverages in the world with abundant 
health benefits (Saeed et al., 2017). The green tea plant originated from Southeast Asia, but is 
cultivated in several continents. (Graham, 1992). The composition of green tea varies with 
climate, season and manufacturing conditions. Catechins are polyphenols found in the leaves 
of green tea. There are four major catechin derivatives, such as EC, epigallocatechin, 
epicatechin gallate and epigallocatechin gallate (EGCG). They are well known for their 
antioxidative, antibacterial, antiviral and anti-inflammatory effects. Recent studies found that 
these polyphenols have many benefits in the prevention and treatment of different diseases such 
as cancer, diabetes and other health concerns (Varilek et al., 2001; Frias et al., 2016). However, 
the mechanism of how the catechins in green tea works and affect the body are still not fully 
understood (Botten et al., 2015).  
 
Figure 8: Illustration of the plant Camellia sinensis (Urtekilden). 
 
The use of natural polyphenols in prevention and treatment of vaginal infections have been 
studied for several decades and the main substance used for this project was EC (Date and 
Destache, 2016).  
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2.6.1 Epicatechin  
EC is one of the active components found in green tea and one of the most important ones. EC 
is considered to have anticancer, anti-inflammatory and antioxidative properties. The substance 
can protect the plant from stress by scavenging reactive oxygen species and protect plants from 
UV radiation from the sun because of its UV absorbing properties. Those effects of EC has 
been associated to their antioxidant activities and makes it suitable for multiple applications in 
the pharmaceutical and food industries (Mendoza-Wilson and Glossman-Mitnik, 2006). The 
mechanism of ECs antioxidant activity has not been proven, although several studies have been 
performed. Most of the studies are still in the experimental and theoretical level (Mendoza-
Wilson and Glossman-Mitnik, 2006; Botten et al., 2015).  
 
Figure 9: Chemical structure of EC. 
 
2.6.2 Antioxidative effects of epicatechin  
Free radicals are atoms or molecules that contains unpaired electrons. Those electrons alter the 
reactivity of the atom or molecule comparable to non-radicals (Lobo et al., 2010). Free radicals 
are formed in the human body by normal metabolic processes caused by physiological stress, 
and by external sources such as environmental radiation, smoking and industrial chemicals 
(Bagchi and Puri, 1998; Frias et al., 2016). Normal levels of free radicals are important for the 
cell signaling processes. High levels of free radicals are harmful and may cause cell damage 
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and death (Lobo et al., 2010). Oxidative stress is a result of imbalance between free radical 
production and antioxidant defense. Oxidative stress has been postulated in many conditions, 
including inflammatory conditions and degenerative disorders. Catechins are well known for 
their antioxidative and anti-inflammatory effects and have the capacity to scavenge free 
radicals, therefore they have a potential in disease prevention and treatment (Lobo et al., 2010; 
Frias et al., 2016) 
There are two pathways for oxidation where antioxidants can have a preventative role (Wright 
et al., 2001). The first one is the hydrogen-atom transfer, based on the capacity of a functional 
phenol group to donate a hydrogen atom to a free radical (R•). The other mechanism is based 
on the single electron transfer from a phenolic antioxidant (ArOH) to a R• with formation of a 
stable radical cation ArOH•+ (Wright et al., 2001).  
• H-atom transfer:    R• + ArOH ® RH + ArO• 
• Single- electron transfer  R• + ArOH ® R- + ArOH•+  
 
It is proposed that EC exhibit its main antioxidative activity through these mechanisms. In 
addition to the mentioned mechanisms, EC can also exhibit protective roles by chelating metal 
ions such as iron and cupper. Structural features for EC that is important for the antioxidative 
activity include the presence of two hydroxyl groups on the B ring at position 3 and 4, and the 
hydroxyl group at R on C ring (Higdon and Frei, 2003).  
 
Figure 10: General structure and nomenclature of catechins. 
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However, EC suffer from poor solubility and low bioavailability. To overcome these problems 
EC should be incorporated into suitable delivery systems such as nanocarriers.  
 
2.6.3 Delivery systems for epicatechin 
Green tea catechins, especially EC, have shown many physiochemical limitations that are 
challenging in the development of new therapeutic agents. Loading EC into nanoparticles can 
increase the absorption and bioavailability, protect EC from degradation by enzymes, enhance 
stability and prolong the circulation time (Chuan et al., 2015; Wang et al., 2014). There are 
several delivery systems that have been considered suitable for EC.  
A study made by Fang et al. developed liposomal formulations of catechins, including EC for 
topical and intratumor applications. They wanted to evaluate the possibility of using liposomes 
for the local delivery, including skin and tumor deposition. They also tried to establish the 
in vivo effect and relationship between physiochemical properties of catechins encapsulated in 
liposomes. The results of this study showed no significant increase in skin deposition of 
catechins after topical administration with liposomes, but a higher amount of catechins in 
liposomal formulation were delivered into the solid tumor than by the aqueous solution with 
catechins (Fang et al., 2005). Another study conducted by Wisiuitiprot et al. investigated the 
cutaneous absorption of catechins from green tea extract alone and loaded catechins from green 
tea extract in chitosan microparticles. The results of the study suggested that chitosan 
microparticles improved the penetration in skin compared to free substances. The results also 
demonstrated that chitosan microparticles limited the degradation of catechins by enzymatic 
degradation on the skin (Wisuitiprot et al., 2011).  
Liposomes have been widely used in different areas such as in drug delivery. Liposomes have 
been studied as a promising carrier system for catechins and several studies have investigated 
the effect of catechins in liposomes (Rodrigues et al., 2013). EC may prevent or treat different 
diseases, but until now, there are no studies of EC in liposomes for topical vaginal application.  
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3 Aim of the study  
The main aim of the study was to develop a liposomal hydrogel delivery system for EC intended 
for local treatment of vaginal infections. Liposomes were expected to enable a controlled and 
sustained release of entrapped EC and the use of hydrogel as vehicle was expected to enable 
mucoadhesion and prolonged residence time at vaginal site.  
The aim can be divided in:  
• Evaluation of the antioxidative effects of EC on DPPH and ABTS+• radicals 
• Characterization of liposomal size, size distribution and EC entrapment efficacy  
• Characterization and optimization of chitosan hydrogel containing liposomal EC, in 
regards to texture properties 
• In vitro EC release testing of liposomal preparations (both suspensions and hydrogels) 
to confirm controlled and prolonged release  
• Determining the ex vivo penetration of EC through sheep vaginal tissue in presence of 
vaginal fluid simulant (VFS) to assure localized EC effect 
• Testing the ex vivo mucoadhesive properties of the liposomal EC hydrogel on cow 
vaginal tissue to prove system´s bioadhesive potential 
• Preliminary testing of the stability of novel system 
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4 Materials and methods 
4.1 Materials 
4.1.1 Materials used 
Acetic acid (glacial), Sigma Aldrich Chemie GmBH, Steinheim, Germany  
Ammonium acetate ≥ 89 %, Sigma Aldrich Chemie GmBH, Steinheim, Germany  
L-Ascorbic acid (Vitamin C), Sigma Aldrich Chemie GmBH, Steinheim, Germany  
2,2- Azino-bis (3-ethylbenzothiazoline-6-sulfonic-acid) diammonium salt (ABTS), Sigma 
Aldrich, Steinheim, Germany  
Bovine serum albumin, Sigma Aldrich Chemie GmBH, Steinheim, Germany 
Calcium hydroxide, Sigma Aldrich Chemie GmBH, Steiheim, Germany  
Chitosan (MMW), Chitinor, Tromsø, Norway  
2,2 Diphenyl-1-picrylhydrazyl (DPPH), Sigma Aldrich Chemie GmBH, Steinheim, Germany 
Distilled water  
Epicatechin, (-)-epicatechin ≥ 90 %, Sigma Aldrich Chemie GmBH, Steinheim, Germany 
Ethanol 96 % vol, Sigma Aldrich Chemie GmBH, Steinheim, Germany  
Glucose ≥ 99.5 %, Sigma Aldrich Chemie GmBH, Steinheim, Germany  
Glycerol, 86-88 %, Sigma Aldrich Chemie GmBH, Steinheim, Germany  
Hydrochloric acid, Sigma Aldrich Chemie GmBH, Steinheim, Germany 
Lactic acid, Sigma Aldrich Chemie GmBH, Steinheim, Germany  
Lipoid S 100, phosphatidylcholine from soybean, Lipoid GmBH, Ludwigshafen, Germany 
Methanol, VWR International S.A.S., Fontenay-sous-Bois, France  
Methanol, Sigma Aldrich Chemie GmBH, Steinheim, Germany  
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Milli-Q water  
Potassium hydroxide, Norsk medisinaldepot NMD, Oslo, Norway 
Potassium peroxidesulfate, Merk KGaA, Darmstadt, Germany 
Potassium phosphate monobasic, Sigma Aldrich Chemie GmBH, Steinheim, Germany 
Sodium chloride ≥ 99.5 %, Sigma Aldrich Chemie GmBH, Steinheim, Germany  
Sodium phosphate dibasic dehydrate, Sigma Aldrich Chemie GmBH, Steinheim, Germany  
 (±)-a-Tocopherol (Vitamin E), Sigma Aldrich Chemie GmBH, Steinheim, Germany 
Trifluoroacetic acid (TFA), Sigma Aldrich Chemie GmBH, Steinheim, Germany  
Ureum (carbamide), Apotekproduksjon AS, Oslo, Norway 
 
4.1.2 Instruments  
Büchi Waterbath B480, Büchi Vac V-500, Büchi vacuum controller B-721, Büchi rotavapor R-
124, Büchi labortechnik, Flawil, Schwitzerland 
Branson B-Series 5510 Ultrasonic Cleaners, Danbury, USA 
Franz Diffusion Cell 15 mm with 12 ml receptor volume, flat ground joint clear glass, clamp 
and stirbar, Permgear, Hellertown, USA  
High Performance Liquid Chromatography, Waters e2795, Separations Module, Waters 2489, 
UV/Visible Detector, Milford, USA  
Julabo heating circulator, Julabo F12-ED, JULABO GmBH, Seelbach, Germany  
NICOMP Submicron particle sizer, model 370, Nicomp Particle Sizing system, Santa Barbara, 
California, USA  
PermGear V6A Stirrer, PermGear, Hellertown, USA 
SpectraMax 190, Microplate Spectrophotometer, Molecular Devocec, Sunnyvale, USA  
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TA.XT.Plus Texture analyzer, Stable Microsystems, Surrey UK. Backward Extrusion Rig 
A/BE, Stable Microsystems, Surrey, UK 
Zetasizer Nano Zen 2600, Malvern Instruments Limited, Engima Business Park, Grovewood 
Road, Malvern, Worcestershire, UK 
 
4.1.3 Computer programs 
High Performance Liquid Chromatography, Empower™ 3 Software, Build 3471, Waters, 2010, 
Dublin, Ireland 
Photon correlation spectroscopy, CW 388 version 1.68, NICOMP Particle Sizing Systems, 
Santa Barbara, California, USA  
Texture analyzer, Exponent, 32 (3.0.5.0) Stable microsystems, Surrey, UK 
Zeta potential, Zeta potential report version 2.2, Malvern Instruments Limited, Malvern, UK 
 
4.1.4 Tissues 
Vaginal tissue from cow was provided by Nortura Målselv, Tromsø, Norway  
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4.2 Methodology 
4.3 Antioxidative assays for epicatechin 
Antioxidative activity is the capacity of EC, vitamin E and vitamin C to scavenge free radicals 
such as ABTS•+ and DPPH. The antioxidative activity of EC was compared with vitamin E and 
vitamin C under the same experimental conditions as mentioned below. 
Stock solutions were prepared of EC, vitamin C and vitamin E in 96 % ethanol to the 
concentrations 1 mg/ml. Sample solutions were prepared by diluting the stock solutions to the 
concentrations 5, 10, 25, 50 and 75 µM.  
 
4.3.1 Measurement of DPPH radical scavenging activity  
DPPH radical scavenging capacity of EC was determined by the method described by Basnet 
et al. (Basnet et al., 2012). DPPH was dissolved in ethanol to the final concentration 134 µM 
and stored in a dark environment at room temperature for 30 minutes before further use. DPPH 
solution (134 µM, 0.3 ml) was mixed with 0.3 ml of each sample solution. The mixed sample 
solutions were shaken and stored in the dark for 30 minutes at room temperature. Determination 
of the antioxidative activity of EC was measured by UV spectrophotometer at wavelength 
519 nm. All experiments were performed in triplicates.  
 
4.3.2 Measurement of ABTS•+ radical scavenging activity  
Equal volumes (2.5 ml) of ABTS•+ solution (7.4 µM) were mixed with potassium peroxidsulfate 
(PPOS) solution (2.6 µM). The reaction mixture was stored in the dark at room temperature for 
3 hours to stabilize. The mixture was then diluted with 96 % ethanol to a final volume of 100 ml. 
ABTS•+ solution (0.3 ml) was mixed with an equal volume of the sample solutions and kept in 
the dark at room temperature. After 30 minutes the absorbance was detected with UV 
spectrophotometer at wavelength 757 nm. All experiments were performed in triplicates.  
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4.4 Liposomal preparation and characterization  
4.4.1 Preparation of liposomes with epicatechin  
Liposomes were prepared by the conventional film method described by Jøraholmen et. al. EC 
(10 mg) and Lipoid S 100 (200 mg) were dissolved in excess methanol in a round bottom flask. 
Methanol was evaporated on Büchi rotavapor R-124 with Büchi Vac V-500 Vacuum Pump 
System for at least 2 hours at 55 mBar and 50°C. The film was then re-suspended in 10 ml 
distillated water and hand shaken until a homogenous suspension. Liposomal suspensions were 
stored in the refrigerator (4-8 °C) overnight before further experiments (Jøraholmen et al., 
2015). 
 
4.4.2 Size reduction of liposomes 
Liposomal size was reduced by extrusion through Nucleporeâ Track-Etch Membrane 
Polycarbonate with different pore sizes. The extrusions were performed 5 times through the 
membranes with pore sizes 0.8 µm, 0.4 µm and 0.2 µm. Liposomal suspension was placed in 
the refrigerator for stabilization overnight before further use.  
 
4.4.3 Vesicle size analysis  
Particle size distributions of the liposomes were measured by photon correlation spectroscopy. 
The determinations were performed on NICOMP submicron Particle Size model 370. To avoid 
any contamination of particles from the environment, the preparations were carried out in a 
laminar airflow bench using particle free equipment. Test tubes were filled with distilled water 
and sonicated for 30 minutes, then rinsed with filtrated water (0.2 µm pore size syringe filter) 
in order to avoid any particles that may interfere during the analysis. The sample was diluted 
with filtrated water to obtain an intensity of 200 - 350 kHz. All analyses were run in vesicle 
mode and intensity distribution. Three parallels, each with a run time of 10 min, were run of 
each sample.  
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4.4.4 Epicatechin calibration curve  
A stock solution was prepared of EC in methanol with the concentration 1 mg/ml. The standard 
solutions were prepared by diluting the stock solution to the concentrations 2.5, 5, 10, 25, 50, 
75 and 100 µg/ml. The UV plate was filled with 200 µl of the solutions in three parallels. The 
absorbance was measured at wavelength 280 nm on UV spectrophotometer. 
 
4.4.5 Entrapment efficiency determination  
Dialysis was used to separate free EC from entrapped liposomal EC, and the dialysis was 
performed in dialysis tubing. One ml of liposomal EC sample was dialyzed against 250 ml 
distilled water for 6 hours. Aliquots of the sample and the dialysis medium were diluted in 
methanol and measured spectrophotometrically at 280 nm to determine the percent entrapment 
efficiency EE (%). 
 
4.5 Hydrogel preparation and characterization  
4.5.1 Preparation of chitosan hydrogel with glycerol 
The preparation of hydrogels were based on the method of Hurler and colleges. Glycerol (10 % 
w/w) was mixed with acetic acid (2.5 % w/w) to a homogenous mixture. Medium molecular 
weight (MMW) chitosan (3 % w/w) was then dispersed in the mixture of glycerol/acetic acid 
and stirred manually for 10-15 minutes. The mixture was bath-sonicated for 30 minutes to 
remove entrapped air. The gel was allowed to swell at room temperature for 48 hours. 
Gels with a starting concentration of 2.5 % (w/w) chitosan and gels with the final chitosan 
concentration of 2.5 % (w/w), after incorporating liposomal EC were also prepared (Hurler et 
al., 2012b).  
 
4.5.2 Incorporation of liposomal epicatechin in chitosan hydrogels  
Different amounts of liposomal EC suspensions, free from unentrapped EC, were incorporated 
into the different chitosan hydrogels. The amount of liposomal EC incorporated was 10 % (w/w; 
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liposomal suspension/total weight) and 20 % (w/w). Liposomal suspension hand stirred to 
evenly dispersed within the chitosan hydrogel (Hurler et al., 2012b).  
 
4.5.3 Zeta potential measurement 
Zeta potential was measured for liposomal EC and the liposomal EC hydrogel. The 
measurements were performed on a Malvern Zetasizer Nano ZS. Before use, the measurement 
cell was rinsed with ethanol and filtrated water (0.2 µm pore size syringe filter). Liposomal EC 
samples (50 µl) was diluted with filtrated water (950 µl). The liposomal EC hydrogel was 
diluted equally, and samples were loaded into the measurement cells. All measurements were 
performed at 25°C and the number of runs for each sample were 3 cycles. 
 
4.5.4 Texture analysis  
To determine the texture properties (cohesiveness, adhesiveness and hardness) of the hydrogels, 
a Texture Analyzer TA.XT plus (Stable micro systems Ltd., Surrey, UK) was used. The 
measurements were conducted by backward extrusion by a probe disk with a diameter of 
40 mm. The analysis was performed on the liposomal EC hydrogel, hydrogels with EC in 
acetate buffer (composition as described below) and plain hydrogels.  
Hydrogels were left in room temperature over the night prior to experiment and 40 g of gel 
formulation were filled in a standard 100 ml beaker. Calibrations were performed, and the 
experimental conditions used for the test were as followed:  
Test mode: compression 
Pre test speed:  4 mm / sec 
Test speed:  4 mm / sec  
Post test speed:  4 mm / sec 
Target mode: distance  
Distance:   10 mm; return to the start point  
Three parameters were measured; maximum compressing force (hardness) (force 1), 
cohesiveness (area 1) and the adhesiveness (area 2) (Figure 11) (Hurler et al., 2012b). Five 
replicate analysis were performed.  
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Figure 11: Parameters measured for texture analysis. 
 
4.5.5 Preparation of vaginal tissue from cow and sheep 
Cow and sheep vaginal mucosa was prepared by removing access fat and underlying tissue. 
The tissues were cleaned with phosphate buffer (pH 7.4), packed in clinging film and frozen 
(- 20 °C). Prior the experiments the tissue was thawed at room temperature.  
 
4.5.6 Mucoadhesive properties 
The mucoadhesion test was performed based on the method of Hurler and Skalko-Basnet 
(Hurler and Škalko-Basnet, 2012). The analysis was performed on a Texture Analyzer TA.XT 
plus (Stable micro systems Ltd., Surrey, UK) with a mucoadhesion rig. Prior the experiment 
vaginal tissue from cow was cut to appropriate sized pieces and rinsed with ethanol and 
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phosphate buffer before the slice was clamped onto the membrane holder. The thickness was 
measured to be around 1.52 mm. Approximately 150 µl of the gel formulations were applied 
onto the probe with a one ml syringe. The die was pinched for exactly 10 sec with a pressure 
of 25 g onto the mucosal tissue. The die was redrawn from the tissue at a speed of 0.1 mm / sec 
until the gel slipped. The detachment force was recorded. 
The mucoadhesive properties were further determined by the amount of the formulation left on 
the tissue. The probe was weighed before and after the tests, and after each measurement, the 
tissue was rinsed with ethanol and phosphate buffer (pH 7.4). All tests were performed in 
triplicates and each formulation was tested five times.  
 
4.5.7 Preparation of acetate buffer 
Acetate buffer (pH 4.6) was prepared by dissolving 38.55 g CH3COOHNH4 in distilled water, 
35 ml glacial acetic acid was added to the mixture and the volume was adjusted to 500 ml with 
distilled water. pH was measured to 4.6.  
 
4.5.8 In vitro release of epicatechin  
To determine the in vitro release of EC from liposome preparations (both suspensions and gels), 
a Franz diffusion cell (FDC) system was used (Figure 12). Before use, donor chamber and 
receptor chamber were well cleaned with methanol for 30 minutes and twice with distilled water 
for 30 minutes. Prior to the experiment the receptor chamber (12 ml) was filled up with acetate 
buffer (pH 4.6) and the heating circulation was set to 37°C. A magnetic stirrer was inserted to 
the receptor chamber to assure a reliable stirring during the experiment. Cellophane membrane 
was evenly cut to fit the top of the receptor chamber and presoaked in acetate buffer for 30 
minutes before use. The membrane was placed on top of the receptor chamber and the donor 
chamber was placed on top with a joint packing in between.  
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Figure 12: Schematic presentation of Franz Diffusion Cell (Sciences, 2010). 
 
Samples (600 µl) were added to the donor chamber and sealed with a rubber plug. The sampling 
ports were covered with parafilm to avoid any evaporation of the acceptor medium. Samples of 
500 µl were collected after 1, 2, 3, 4, 6 and 8 hours. After each sampling the volume taken out 
was replaced with fresh buffer. When the last samples were taken, the residue in the donor 
chamber was collected and the membrane was left in methanol. All samples were diluted in 
methanol and drug content was determined with UV spectroscopy as described above. 
Following preparations were tested (all samples were prepared with the same concentration of 
EC; Control (EC in acetate buffer), liposomal EC (liposomal EC in distilled water), control in 
hydrogel (EC in acetate buffer in hydrogel) and liposomal EC hydrogel.  
 
4.5.9 Preparation of vaginal fluid simulant  
VFS was prepared from 3.51 g/l NaCl, 1.40 g/l KOH, 0.222 g/l Ca(OH)2, 0.0018 g/l bovine 
serum albumin, 2 g/l lactic acid, 0.16 g/l glycerol, 0.4 g/l urea, 5 g/l glucose, distilled water and 
0.1 M HCl to adjust the pH to 4.5 (Owen and Katz, 1999). 
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4.5.10 Preparation of phosphate buffer  
Phosphate buffer (pH 7.4) was composed of 8 g/l NaCl, 0.19 g/l KH2PO4 and 2.38 g/l Na2HPO4. 
pH was adjusted with NaOH.  
 
4.5.11 Ex vivo penetration of epicatechin 
Sheep vaginal tissue was used for the ex vivo penetration study and thawed in phosphate buffer 
before sectioning small pieces to fit the franz cells. Excess fat was removed, and the thickness 
of the pieces aimed to be the same. The thickness was measured to be around 1.1 mm. Prior to 
the penetration experiments the receptor chambers (12 ml) were filled with phosphate buffer 
(pH 7.4). Samples (550 µl) were added to the donor chamber with VFS (50 µl). Following 
preparations were tested; Control (EC in acetate buffer), liposomal EC (liposomal EC in 
distilled water) and liposomal EC hydrogel. 
The samples were filtrated through Acrodisk® 13 mm Syringe Filter with 0.2 µm Nylon 
Membrane. After the filtration, the samples were diluted in methanol and the content of EC was 
determined by HPLC. The method used in HPLC analysis was based on the method described 
by Li et al. (Li et al., 2012). A reverse phase column (Symmetryâ C18 5µ: 3.9x150 mm 
Column, Waters, Dublin, Ireland) installed in a Waters e2795 separations module coupled to a 
Waters 2489 UV/Visible detector were used in the measurements. The mobile phase consisted 
of 0.1 % TFA in Milli-Q water (pH=2.0) mixed with methanol in a ratio 75:25 (v/v). The HPLC 
measurement settings were as follows: flow rate 0.8 ml / min, column temperature 25 °C, 
sample temperature 25 °C, injection volume 20 µl, run time 13 min and the detection 
wavelength 280 nm. The measurements were performed in triplicates. 
 
4.6 Statistical evaluation  
When suited, a student t-test were performed to determine the level of significance. The 
significance level was set to P ≤ 0.05.  
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5 Results and discussion  
5.1 Antioxidative potential of epicatechin, vitamin C and vitamin E 
In order to evaluate and compare the in vitro antioxidative effect of EC with vitamin C and 
vitamin E, well established antioxidants, the DPPH and ABTS+• radical scavenging assays were 
utilized. The assays are widely used to determine the antioxidative activity of different 
substances, due to the wide availability, simplicity and accuracy (Basnet et al., 2012; Kedare 
and Singh, 2011; Erel, 2004). 
The antioxidative activity of EC is expressed as the capacity to scavenge the stable free radicals 
of DPPH and ABTS+•. Both DPPH and ABTS+• are concentration dependent where higher 
concentrations correlate to high absorbance and lower concentration to low absorbance. This is 
also reflected in the colour change; the DPPH and ABTS+• are deep violet and deep green 
colour, respectively; and a decrease in colour intensity indicates a decrease in absorbance, 
corresponding to the decrease in free radicals concentration (Kedare and Singh, 2011; Erel, 
2004).  
 
Figure 13: DPPH radical scavenging activities (%) of epicatechin ± SD (n=3). 
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Figure 14: ABTS+• radical scavenging activities (%) of epicatechin ± SD (n=3). 
 
EC is well known for its antioxidative activities, thus, its activities was compared to those of 
vitamin C and vitamin E. Vitamin C is a water-soluble substance and vitamin E is a lipophilic 
substance, that are well known for their antioxidative effects (Dreosti, 2000). The antioxidant 
concentrations chosen were 5, 10, 25, 50 and 75 µM; all the concentrations were measured at 
the same time. EC, vitamin C and vitamin E expressed a concentration-dependent radical 
scavenging activity for both ABTS+• and DPPH (Figures 13 and 14), where higher 
concentrations of the antioxidants corresponded to more of the free radicals being scavenged. 
The concentration-dependent scavenging activity indirectly indicates that the substances 
solubility does not affect its antioxidative activity. 
EC expressed a slightly superior antioxidative effect towards ABTS+• than DPPH (Figure 13 
and 14). The differences in radical scavenging activity may be due to the structural differences 
between the radicals used and how they react with EC (Cai et al., 2006). The radical scavenging 
activity of vitamin C and vitamin E were almost identical in both.  
In order to consider the differences in antioxidative activity among EC, vitamin C and 
vitamin E, we used an independent t-test where all absorbance values of EC were paired with 
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the comparable values for vitamin C and vitamin E at the same concentrations. The independent 
t-test was performed for all concentrations and both ABTS+• and DPPH measurements. For 
DPPH measurements we found that EC was significantly more potent compared to both 
vitamin C and vitamin E. Our findings are supported by other studies reporting that catechins 
and EC are more efficient scavengers of DPPH radicals than both vitamin C and vitamin E 
(Higdon and Frei, 2003; Nanjo et al., 1996). Figure 14 indicates that EC is more potent 
antioxidant in lower concentrations than both vitamin C and vitamin E, which is favourable 
considering that the amount of EC in the hydrogel formulations is expected to be low (discussed 
below). Vitamin C was found to have a better antioxidative effect than EC in the concentration 
of 50 µM. Results of the t-test indicated that vitamin C was significantly stronger antioxidant 
than EC in that concentration.  
As mentioned, we found that ECs radical scavenging effects on ABTS+• were much stronger 
than for DPPH, especially in the lower concentrations (Figure 14). The results from the 
independent t-test confirmed that EC was significantly more potent antioxidant than both 
vitamin C and vitamin E (P ≤ 0.05 for all substances), in the lower concentration. This 
correspond to the findings of Higdon and Frei who reported that the radical scavenging activity 
of EC was greater than both vitamin C and vitamin E (Higdon and Frei, 2003).  
The results confirmed that EC exhibits strong radical scavenging effects. EC has many health 
beneficial properties; however, it suffers from several physiochemical limitations such as low 
solubility and limited bioavailability. To overcome these limitations and increase the biological 
activity especially for vaginal infection targeting, liposomal EC incorporated in chitosan 
hydrogel was proposed. Therefore, current research was mainly focused on the development of 
a liposomal hydrogel delivery system for EC. 
 
5.2 Liposomal characterization  
The physiochemical characteristics of the delivery system are important for the effectiveness 
of local drug delivery to the vaginal tissue. The size of vesicles can affect system´s ability to 
pass through mucin pores, thus, it is an important parameter to measure (Vanić and Škalko-
Basnet, 2013). According to Samad et al. the thin film method used to prepare liposomes 
provide large vesicles often larger than 1 µm in diameter (Samad et al., 2007). Smaller 
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liposomes with uniform size distribution are preferred for improved drug delivery properties, 
hence, a reduction of liposomal size is needed.  
One of the most common methods for size reduction of liposomes is by extrusion (Berger et 
al., 2001). This method is based on size reduction by input of mechanical energy to push an 
aqueous lipid suspension through the polycarbonate membranes with defined pore sizes. Based 
on the vaginal mucus physiology the mesh pore sizes are estimated to be around 340 ± 70 nm 
(Lai et al., 2010). Considering the optimal size of particles intended for vaginal drug delivery, 
there are very few studies reporting the effect of vesicle size. However, a study conducted by 
Takeuchi et al. indicated that a reduction in liposomal size to approximately 100 nm increased 
the penetration through intestinal mucus. This finding cannot be directly correlated to the 
penetration through vaginal mucosa. On the other hand, das Neves et al. suggested that a size 
range between 200-500 nm is preferable for vaginal mucosal delivery, since both larger and 
smaller nanosystems failed to achieve mucus penetration (das Neves et al., 2011b; Takeuchi et 
al., 1996).  
In this project the membrane pore sizes chosen for the extrusion were 800, 400 and 200 nm to 
achieve a desired vesicle size around 200 nm, and the obtained liposomes were found to be in 
the desired size range (Table 1).  
 
Table 1: Characterization of liposomes containing epicatechin.  










197.89 ± 26.83 0.074 81.46 ± 1.61 -1.52 ± 2.03 
The values are presented as mean ± SD (n=3). 
 
Advantages of using extrusion as a method to reduce the liposomal size is the easiness of 
achieving the desirable size and a more uniform size distribution, which is favourable. A PI 
below 0.7 is acceptable, however, it indicates a broad distribution, thus a PI below 0.3 is 
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preferable and considered a more homogenous size distribution. Many studies use sonication 
as a size reduction method which is not optimal due to the difficulties to achieve the desirable 
size and increased stress to the liposomes that may cause deformation or loss of entrapped 
substance (Patil and Jadhav, 2014; Akbarzadeh et al., 2013). Table 1 indicates that PI for our 
liposomes were lower than 0.1 that indicates a very homogeneous size distribution. The low PI 
also confirmed that extrusion is a suitable method to achieve desired vesicle size with limited 
polydispersity.  
It is suggested that EC is incorporated in the lipid bilayers of liposomes (Hashimoto et al., 
1999). The physiochemical properties of EC will affect the incorporation efficiency and the 
solubility of the substance is crucial. Due to the lipophilic nature of the drug (logP of 1.8 
(Drugbank), EC was dissolved with the lipid in methanol prior to liposomes preparation and 
was expected to be incorporated within the lipid bilayer. To assure a sufficient amount of active 
substance able to achieve an optimal therapeutic effect, a high entrapment efficiency of the 
active substance in the liposomes is desirable (Pavelić et al., 2001). According to Basnet et al. 
there is a balance between the vesicle size and entrapment efficacy where a reduction in vesicle 
size leads to reduced entrapment efficacy, due to reduced number of lipid bilayers available to 
accommodate lipophilic substances (Basnet et al., 2012). As described earlier, free EC was 
separated from liposomal EC by dialysis. Dialysis principle is based on separating entrapped 
substance from the non-entrapped substance using dialysis tubes and aqueous medium. Time 
used in dialysis was set to 6 hours considering that this is enough time to remove free EC. It is 
known that dialysis can be used as a release method, a longer dialysis of EC could lead to 
release of incorporated EC. The dialysis was performed in the sink conditions, to assure that 
free EC, with limited solubility in water, can be separated from liposomal EC. 
The entrapment efficiency was calculated on the basis of a standard curve for EC, and a 
representative standard curve used in the calculation is shown in Figure 15. The correlation 
coefficient was determined to be 0.999. The entrapment efficiency (EE) for EC was found to 
be 81.46 ± 1.61 % (Table 1). The entrapment was slightly higher than previously reported data; 
Fang et al. reported EE from 20 – 67 % depending on type of liposomes; Jain et al. reported 
EE of 64.7 % for extruded liposomes with EC (Fang et al., 2006; Jain et al., 2013). However, 
Huang et al. have shown similar entrapment values for EC (Huang et al., 2011). The mentioned 
studies refer to different lipid composition and preparation methods used for liposome 
preparation. When determining the EE, the method of separation of free drug from liposomally-
associated drug can affect the EE to certain degree. Lipophilic compounds can also be separated 
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from liposomes by centrifugation, depending on their size. The use of this method can cause a 
higher strain to the liposomes and an increased loss of liposomally associated substance, in 
addition, larger liposomes may settle at the bottom and be removed, which may be an 
explanation for lower entrapment reported in the above mentioned studies.  
Figure 15: Calibration curve of epicatechin in methanol. 
 
Zeta potential is used to characterize the surface charge of nanoparticles, such as liposomes 
(Singh and Lillard, 2009). Zeta potential is defined as the electric potential in the interfacial 
double layer of colloidal systems (Honary and Zahir, 2013). The surface charge of liposomes 
can be influenced by the liposomal compositions and the medium dispersed in. Positively 
charged vesicles are expected to interact with the negatively charged mucus layer by 
electrostatic interactions (Singh and Lillard, 2009). Vesicles with a net charge near neutral may 
achieve better mucus penetrating properties by avoiding interactions with mucus (Cu and 
Saltzman, 2008). Our liposomes were composed of PC and EC, and the zeta potential was 
expected to be neutral as a result of the neutral lipids used in liposome preparation 
(Pasenkiewicz-Gierula et al., 1999). It is expected that neutral liposomes will interact less with 
chitosan hydrogel (Hurler et al., 2013). Our liposomes were slightly negative with a zeta 
potential of -1.52 ± 2.03 (Table 1); the results were supported by literature (Fang et al., 2006). 
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The slightly negative zeta potential may be caused by a minor lipid oxidation due to exposure 
to air (Reis and Spickett, 2012).  
 
5.3 Hydrogel characterization  
In order to make the liposomal suspension applicable for vaginal administration and prolong 
their residence time at the site of action, the liposomes was incorporated in a chitosan hydrogel 
which functions as a vehicle for the liposomes. Prolonged residence time at the site of action 
improves the therapy by increasing the contact time between the active substance and the 
administration site (Pavelić et al., 2001). It can also reduce the frequency of administration and 
contribute to improved patient compliance. Considering that the mucus is negatively charged 
due to the anionic substructures in the mucus, ionic interaction between the cationic amino 
groups of chitosan and vaginal mucus can occur (Bernkop-Schnürch and Dünnhaupt, 2012). In 
this project we used chitosan hydrogel and the overall positive surface charge was confirmed 
by the measured positive zeta potential (Table 2). 
 
Table 2: Zeta potential of liposomal EC hydrogel. 
Type of hydrogel Zeta potential (mV) 
Liposomal EC hydrogel  
(2.5 % chitosan, 20 % liposomes (w/w)) 
75.62 ± 1.98 
The value is presented as mean ± SD (n=3). 
 
The texture properties of the hydrogels are important parameters for topical formulations, as 
they will affect the applicability of the formulation and therapeutic efficacy at the 
administration site (Hurler et al., 2012b). To assure that the properties of our hydrogels correlate 
to the desired properties, we investigated the cohesiveness (Area 1), adhesiveness (Area 2) and 
the hardness (Force 1) (Figure 11) for different hydrogel formulations containing liposomal 
EC. The texture properties are presented in Figure 16.  
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Figure 16: Texture properties of different liposomal EC hydrogels, the values are presented as 
mean ± SD (n=2). * Final concentration of chitosan (w/w). 
 
Important features of gels are gel cohesiveness, adhesiveness and hardness, considering 
optimization of the gel properties (Hurler et al., 2012b). The adhesiveness together with the 
cohesiveness give an indication of the retention time at the site of action while the hardness of 
the formulation indicates the applicability of the gel onto tissue and those are directly correlated 
to the polymer concentration (Hurler et al., 2012b). As presented in Figure 16, the hardness, 
cohesiveness and adhesiveness increase with increased chitosan concentration. Sezer et al. 
reported similar observations, where the gel adhesiveness, cohesiveness and hardness increased 
with the increase in chitosan concentration (Sezer et al., 2008). However, the experimental 
setup as well as the compositions were different to those in this project. The hydrogels used for 
further experiments consisted of 2.5 % (w/w) chitosan and 20 % (w/w) incorporation of 
liposomal EC although this hydrogel exhibited the lowest values of the tested parameters, the 
formulation was still considered to be acceptable for vaginal application and further use. 
Table 3 represent the texture properties of the hydrogels used in further experiments.  
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Table 3: Texture properties of liposomal EC hydrogel.  
Type of hydrogel Force 1 (g) Area 1 (g x sec) Area 2 (g x sec) 
Liposomal EC hydrogel  
(2.5 % chitosan,  
20 % liposomes (w/w)) 
70.15 ± 0.62 158.53 ± 0.89 -93.42 ± 1.33 
The values are presented as mean ± SD (n=3).  
The preparation method used for the hydrogels was simple and the texture properties indicate 
that the method produced reproducible hydrogels, as indicated by the small standard deviations.  
Hurler et al. investigated the influence of glycerol and liposomes when incorporated into a 
chitosan hydrogel and reported stabilizing effect of glycerol on the chitosan gel structure 
(Hurler et al., 2012b). To confirm the proposed glycerol effect, we tested hydrogels with 
different concentrations of glycerol (Table 4). 
Table 4: Texture properties of plain hydrogel, liposomal EC hydrogel with different amount 
of glycerol and control in hydrogel. 
Type of hydrogel Force 1 (g) Area 1 (g x sec) Area 2 (g x sec) 
Plain hydrogel* 65.09 146.87 - 80.05 
Control** in hydrogel* 
(2.5 % chitosan,  
20 % liposomes (w/w)) 
59.79 134.28 - 69.52 
Liposomal hydrogel* 
(2.5 % chitosan,  
20 % liposomes (w/w)) 
71.01 159.79 - 94.31 
Liposomal hydrogel***  
(2.5 % chitosan,  
20 % liposomes (w/w)) 
66.29 148.09 - 86.27 
The values denote the mean of 5 runs (n=1), * Amount of glycerol in the formulations is 10 % 
(w/w,) ** EC in acetate buffer. *** Amount of glycerol in the formulation is 5 % (w/w). 
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Table 4 reports slight differences in the gel properties of the different formulations. Liposomal 
EC hydrogels exhibited better cohesiveness, adhesiveness and hardness compared to the empty 
hydrogel and the control in hydrogel. Hurler et al. reported similar findings where the addition 
of liposomal dispersion to a glycerol/chitosan hydrogel increased the cohesiveness, hardness 
and adhesiveness of the hydrogel (Hurler et al., 2012b). Ruel-Gariepy et al. reported that 
incorporation of liposomes into a chitosan-b-glycerophosphate gel expanded the gel strength, 
however this was concentration-dependent and inclusion of higher amounts of liposomal 
suspension led to decrease in gel strength (Ruel-Gariepy et al., 2002). In order to confirm the 
effect of the incorporation of liposomes into the hydrogel, more testing is needed. In addition, 
Hurler et al. claimed that glycerol stabilizes the chitosan network (Hurler et al., 2012b). Table 4 
indicates better cohesiveness, adhesiveness and hardness for the formulation with higher 
glycerol content. However, more research is needed, including testing over a longer period of 
time to investigate if the concentration of glycerol will affect the stability of the hydrogel. In 
addition, several parallels would assist in drawing a conclusion. Our results can therefore be 
considered as an indication of a trend. 
To investigate the stability of chitosan hydrogel a stability test was performed where the texture 
properties were measured after the storage in the refrigerator (4-8 °C) for one and two months 
(Table 5). 
 
Table 5: Texture properties of liposomal EC hydrogels (2.5 % chitosan and 20 % liposomes 
(w/w)) after storage. 
Measurements 
after (n) months 
Force 1 (g) Area 1 (g x sec) Area 2 (g x sec) 
0 70.45 ± 0.52 158.79 ± 1.62 -92.93 ± 2.20 
1 66.03 ± 0.30 147.78 ± 1.73 -87.62 ± 2.63 
2 63.57 ± 0.95 144.04 ± 2.11 -78.29 ± 3.01 
The values denote the mean of 5 runs (n=2). 
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As shown in Table 5 we could observe a slight decrease in the values from the measurements 
after one and two months of storage. The decline in the values was not considered critical; 
however, further investigation is needed especially for gels stored at room temperature. It would 
be beneficial to include more parallels in the testing. 
To obtain an optimal therapeutic effect, the formulation applied to the vaginal mucosa should 
enable a prolonged residence time. Mucoadhesion is an important parameter for optimization 
of drug delivery systems, as it can influence substance retention and subsequently, its 
bioavailability. To mimic the in vivo conditions, the barrier used in the experiment was vaginal 
mucosal tissue from cow, since the cow vaginal mucosa is a good simulation of human vaginal 
mucosal properties (das Neves et al., 2008). The results are presented as the detachment force 
in Figure 17; the detachment force is defined as a force needed to overcome the adhesive bonds 
between the formulation and the mucus. This force can also be correlated to the cohesiveness 
of the formulation (Hurler and Škalko-Basnet, 2012).  
 
 
Figure 17: Mucoadhesiveness of three liposomal EC hydrogels determined as detachment 
force. The figure represent the mean of five runs for each formulation. 
 
The formulations represented in Figure 17 and 18 are liposomal hydrogels prepared in triplicate 
comprising the same concentration of chitosan and incorporated liposomal EC. Liposomal 
hydrogel with 3 % chitosan and 20 % liposomes (w/w) was tested only one time and is not 
included. Figure 17 indicates that the force needed to detach the formulation from the tissue is 
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relatively similar. Given the similarity of the gel formulations it is expected good 
reproducibility, however, there are some variation and may be due to the soft vaginal tissue 
(discussed below). To provide a deeper insight on the mucoadhesion of the formulations, 
determination of the exact amount retained on the tissue was performed.  
 
Figure 18: Mucoadhesiveness of three liposomal EC hydrogel formulations determined as the 
amount of retaining formulation on vaginal tissue. The figure represents the mean of five runs 
of each formulation. 
 
The amount of formulation retained on the tissue after removing the die/probe is presented in 
Figure 18. The results indicate that high amounts were retained on the tissue and the results 
indicate good reproducibility due to only slight variation in the measurements. For the chitosan 
hydrogels, the detachment forces reported by Hurler and Skalko-Basnet (2012) were similar as 
our results, however the amounts of formulation retained on the tissue were higher in our study 
(75 - 85 %) compared to Hurler and Skalko-Basnet (2012) who reported about 50 % of 
formulation retained on the skin. An explanation of the differences can be attributed to the 
different tissues used. Skin as a tissue is much more rigid and robust, whereas vaginal tissue is 
very soft and rather slippery. After each measurement the tissue was rinsed with ethanol and 
phosphate buffer, which may affect the integrity of the tissue, however, the method is 
reproducible and the same cow mucosa sample where used up to five times. The results are not 
entirely close to in vivo conditions considering that the experiments were performed in the 
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absence of VFS. The reason VFS was not applied were due to difficulties in adjusting for the 
additional liquid. According to das Neves et al. the use of VFS is important as it may influence 
the performance of the test (das Neves et al., 2008). However, the time did not permit us to 
optimize the bioadhesion study and allow for the use of VFS.  
Another method tested was with vaginal tissue attached to the probe where the mucosal surface 
covered the lower end of the probe. The probe with tissue was then lowered until it touched the 
gel surface on a beaker and then retracted to the starting position. However, the results were 
not included due to high variations in the detachment force. The instrumental setups for this 
measurement was developed for studies on skin and might not be optimal for vaginal mucosal 
tissue (Hurler and Skalko-Basnet, 2012).  
  
5.4 In vitro release of epicatechin  
In the optimization of a drug delivery system, a controlled release of the substance is an 
essential parameter. To evaluate the release of EC from liposomal preparations (both as 
suspensions and suspension-in gels), an in vitro study was performed. FDC systems is 
considered as one of the most appropriate in vitro method for evaluating the drug release from 
different formulations such as those destined for vaginal use (das Neves and Bahia, 2006). The 
FDC was used in our release studies. As the main focus of the project was localized vaginal 
drug delivery, the experimental setups were closely mimicking the human conditions; the 
acceptor medium (pH 4.6) simulated the pH of the healthy vagina (4.5-5.5), and the temperature 
was set to 37 °C (das Neves and Bahia, 2006). The release profile of EC was evaluated for 
8 hours considering that the vaginal discharge, presence of semen or menstruation can 
contribute to the clearance of formulation from the vagina (das Neves et al., 2011a). The release 
profile of EC through cellophane membrane is presented in Figure 19.  
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Figure 19: In vitro epicatechin (EC) release from different formulations through cellophane 
membrane (n=3). EC concentration in all formulations was ~120 µg. *EC in acetate buffer. 
 
A more prolonged release would be favourable to reduce frequency of administrations, which 
is considered favourable for the patient. In order to confirms that the prolonged release is indeed 
due to the liposomes as carrier system and their incorporation in hydrogel, EC in acetate buffer 
as well as hydrogel containing EC in buffer were used as the controls. Figure 19 indicates that 
the release rate of EC from the liposomal hydrogel is slower than from the other formulations, 
as expected. After 8 hours, the release of EC from our liposomal hydrogel was approximately 
40 µg. Additionally, it is essential that the active substances are released in a quantity able to 
induce a desired therapeutic effect. However, this cannot be evaluated in an in vitro study, and 
would require at least artificial vaginal tissue model. Another interesting finding observed was 
the release of EC from the control in hydrogel, which was slower than for liposomal EC. This 
indicates that the hydrogel plays an important role in defining the release profile of entrapped 
substances, especially in the dual system such as liposomes-in-hydrogel. Liposomes are known 
to prolong the release of different substances in synergy to hydrogels, however, our findings 
indicate that the hydrogel is the actual rate limiting step. Considering the ECs structure and 
logP of 1.8, it is expected that the substance would be preferably retained in the liposomal 
bilayer due to its lipophilicity and release would be slower than from a hydrogel.  
A study conducted by Vanic et al. investigated the in vitro drug release from liposomal 
hydrogels under the conditions simulating vaginal environment. The results of the study showed 
 
Page 49 of 63 
great potential of liposomal hydrogel as an efficient delivery system for the controlled and 
sustained release of antimicrobial drugs in the vagina (Vanić et al., 2014). Mulik et al. 
investigated the release properties of cytatabine-loaded liposomes incorporated in a gel in 
comparison with free catatabine in gel. The study confirmed sustained release from the 
liposomal gel (Mulik et al., 2009). Another study by Pavelic et al. optimized liposomal drug 
carrier system, able to provide sustained and controlled release of drug for local vaginal therapy. 
Liposomes containing model molecule calcein were incorporated in Carbopol gels and calcein 
in vitro release was evaluated. The study confirmed that incorporation of liposomes in Carbopol 
gels resulted in a novel drug carrier system for vaginal delivery (Pavelić et al., 2001).  
Many studies indicated that incorporation of liposomes into a hydrogel led to prolonged release 
of active ingredient, the studies cannot be directly compared due to the different substances 
used in different delivery systems in addition to the differences in experimental setups. It is 
rather misleading to directly compare the release of hydrophilic molecules to the release of 
lipophilic molecules from liposomes. The lower release of EC from liposomal hydrogel may 
also be contributed to the amount of active substance incorporated into the hydrogel as well as 
the chitosan concentration. Dragicevic et al. reported that increase in polymer concentration 
can lead to a decrease in the release of liposomally entrapped drug for liposomal carbomer 
(Carbopol) hydrogels (Dragicevic-Curic et al., 2009).  
 
5.5 Ex vivo penetration of epicatechin 
After assuring that the liposomal formulation is able to release EC for potential penetration, the 
next focus was on the penetration profile of EC, in respect to the time. Thus, the next step was 
to determine ex vivo penetration of EC through a vaginal mucosal tissue to get a closer insight 
on the possible in vivo situation. To determine the ex vivo tissue penetration of EC, FDC was 
used as this method is well known to be suitable for this purpose (das Neves et al., 2013; 
Jøraholmen et al., 2015). When aiming for local treatment at the vaginal site a limited 
absorption of the substance is desirable; assuring that a higher drug concentration at the vaginal 
site is achieved. To closer mimic the in vivo conditions, the barrier used for the experiment was 
vaginal tissue from sheep, as the sheep vagina is rather similar to human vagina (Holt et 
al., 2015). Sheep vaginal epithelium is stratified squamous tissue comparable to the human 
(Moss et al., 2012). The experimental setup was the same as for in vitro EC release, except for 
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the acceptor chamber where the medium was phosphate buffer simulating the pH in blood (pH 
7.4). To further mimic in vivo conditions, the VFS was included in the donor chamber.  
 
Figure 20: Epicatechin (EC) distribution (%) in ex vivo studies (8 hours) on sheep vaginal 
tissue (n=2). * EC in acetate buffer. 
  
In the ex vivo penetration studies, three formulations were included; liposomal EC hydrogel, 
liposomal EC suspension and control EC solution (EC in acetate buffer). Figure 20 indicates 
that EC from the control had the highest amount of penetration through the tissue relative to the 
other formulations, possibly due to the lack of a release controlling vehicle. The amount 
penetrated from liposomal EC were approximately around 50 % and lower than expected 
considering that from the in vitro release study, where a higher amount of EC was released 
relative to the other formulations. Liposomal EC had the lowest amount of EC penetrated 
compared to the other formulations. In addition, non-penetrated EC was the highest for the 
liposomal EC.  
Figure 20 indicates a higher amount of EC penetrated from the liposomal hydrogel formulation 
as compared to liposomal EC. An explanation for this can be attributed to chitosan as it is 
known that chitosan has permeation enhancing properties and may act on the sheep tissue 
through decomposition of the tight junctions (Bernkop-Schnürch and Dünnhaupt, 2012), 
allowing EC penetration. In addition, the amount of EC retained in the tissue and non-
penetrated EC were higher. A higher amount retained in the tissue for the liposomal hydrogel 
is considered favourable regarding the non-invasive treatment of HPV. Considering that local 
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HPV treatment should reach deeper into the vaginal mucosal tissue and obtain a prolonged 
release within the affected tissue, while avoiding high systemic levels (Foldvari, 2012), our 
findings are encouraging.  
In order to evaluate the differences in the EC penetration from different formulations an 
independent t-test was performed for all formulations and the determined amount of penetrated 
EC (%). The t-test indicated that liposomal EC and liposomal EC hydrogel showed significantly 
reduced penetration of EC compared to the control.  
A control experiment with pure phosphate buffer (pH 7.4) in the donor chamber was performed 
under the same experimental setup to eliminate interference of tissue in the measurements. The 
results from this experiment indicated that even where there was no EC present (buffer alone 
as control), and those readings were taken into account when determining the EC concentration. 
In order to come closer to the evaluation in in vivo conditions, further investigation is needed, 
including the anti-inflammatory potentials, safety and toxicity studies.  
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6 Conclusions  
The present research was focused on the development of a liposomal EC hydrogel for local 
vaginal therapy. EC exhibited strong antioxidative effects, as confirmed by its ABTS+• and 
DPPH scavenging activity and was found to be superior to both vitamin C and vitamin E at 
lower concentrations. Liposomes prepared by the thin film method were shown to incorporate 
high amount of EC; by applying extrusion as a size reduction method we were able to prepare 
rather homogenous liposomes in the desired size range. Liposomal EC hydrogel exhibited 
acceptable textural properties along with mucoadhesive properties enabling prolonged retention 
time at vaginal site. In addition, the formulations were shown to provide prolonged release both 
for liposomal EC and liposomal EC hydrogel, which is favourable for vaginal application. EC 
may be effective in prevention and treatment of vaginal infections, however further 
investigation is needed. The ex vivo penetration study indicated that EC penetrated to some 
extent into and through vaginal mucosal tissue, however, more studies and optimization of the 
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7 Prospective 
Further optimization of ex vivo mucoadhesion measurements for semisolid formulations 
applied to mucosal tissues are required, as there are no validated methods available so far. 
Further, several testing conditions that closely mimic the vaginal environment, such as 
temperature, pH and the presence of vaginal fluid simulant or semen simulant should be 
investigated as it will affect the mucoadhesiveness of the formulation destined for vaginal site. 
In addition, stability testing at room temperature conditions for liposomal EC and liposomal 
EC hydrogel should be carried out, as well as the stability in vaginal environment. The method 
used to determine amount of EC in ex vivo penetration studies should be optimized due to the 
interference from the tissue. However, our data can serve as a very good starting point in further 
optimization. 
Evaluation of anti-inflammatory and antimicrobial properties of EC is necessary and further 
investigation is needed. In addition, evaluation of cellular toxicity of liposomal EC and 
liposomal EC hydrogel should be performed. Moreover, the possible interference of novel 
delivery system on the vaginal flora should be performed to prove its safety. Finally, in vivo 
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